Addus HomeCare - ADUS Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addus HomeCare in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADUS shares.
View ADUS analyst ratings or view top-rated stocks.

5 brokerages have issued 1-year target prices for Addus HomeCare's shares. Their ADUS share price forecasts range from $101.00 to $130.00. On average, they expect the company's stock price to reach $110.40 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price.
View analysts price targets for ADUS or view top-rated stocks among Wall Street analysts.

Addus HomeCare's stock was trading at $93.51 at the beginning of the year. Since then, ADUS stock has decreased by 0.2% and is now trading at $93.29.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our ADUS earnings forecast.

Addus HomeCare Co. (NASDAQ:ADUS) issued its quarterly earnings results on Monday, August, 1st. The company reported $0.91 EPS for the quarter, missing the consensus estimate of $0.92 by $0.01. The company had revenue of $236.94 million for the quarter, compared to analyst estimates of $238.40 million. Addus HomeCare had a net margin of 4.90% and a trailing twelve-month return on equity of 8.63%. Addus HomeCare's revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $0.78 EPS.

91 employees have rated Addus HomeCare Chief Executive Officer Dirk Allison on Glassdoor.com. Dirk Allison has an approval rating of 51% among the company's employees. This puts Dirk Allison in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Addus HomeCare investors own include AbbVie (ABBV), Bank of America (BAC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Verizon Communications (VZ), CVS Health (CVS), Pfizer (PFE), Ulta Beauty (ULTA), Cisco Systems (CSCO) and Walt Disney (DIS).

Addus HomeCare trades on the NASDAQ under the ticker symbol "ADUS."

Addus HomeCare's stock is owned by many different institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (3.76%), State Street Corp (3.47%), WCM Investment Management LLC (3.34%), Price T Rowe Associates Inc. MD (2.37%), Northern Trust Corp (1.82%) and Kennedy Capital Management Inc. (1.74%). Insiders that own company stock include Brian Poff, Darby Anderson, David W Tucker, Esteban Lopez, Laurie Manning, Mark L First, Michael D Wattenbarger, R Dirk Allison, Roberton James Stevenson, Sean Gaffney, Susan T Weaver and W Bradley Bickham.
View institutional ownership trends.

Shares of ADUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADUS stock can currently be purchased for approximately $93.29.

Addus HomeCare (NASDAQ:ADUS) has a market capitalization of $1.50 billion and generates $864.50 million in revenue each year. The company earns $45.13 million in net income (profit) each year or $2.76 on an earnings per share basis.

The company employs 31,915 workers across the globe.

Addus HomeCare's mailing address is 6801 GAYLORD PARKWAY, FRISCO TX, 75034. The official website for the company is www.addus.com. The company can be reached via phone at (469) 535-8200, via email at investorrelations@addus.com, or via fax at 630-487-2707.